China Livzon Pharma affiliate’s COVID-19 vaccine candidate enters phase III trial
- Advertisement -
Most Popular
Indonesia’s US$52 billion fund to invest 5% of assets abroad
The plan marks a key shift for BPJS TK has outgrown Indonesia’s shallow capital markets
